FLT4 and arthritic joint disease: VEGF-C/VEGFR3 treatment. The VEGF-C/VEGFR3 signaling pathway represents a prominent target for increasing lymphangiogenesis and enhancing lymphatic drainage capacity, thereby suggesting that elevating the content of VEGF-C or selectively targeting LECs with VEGFR3 within joints may hold promising therapeutic potential in arthritis.